Skip to main content

Lipocine Inc.

LPCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001535955

No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Lipocine Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of LPCN: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders3338+5
Shares9.13M9.19M+59.3K (+0.7%)
Value$12.8M$10.0M−$2.76M (−21.6%)

New holders (7)

Institutions that held Lipocine Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to LPCN in Q3 2021
InstitutionSharesValue% of portfolio
Citadel Advisors LLC55,620$61.0K0.00%
Susquehanna International Group, LLP39,697$43.0K0.00%
Jane Street Group, LLC37,482$41.0K0.00%
Virtu Financial LLC30,069$33.0K0.00%
Qube Research & Technologies Ltd24,075$26.0K0.00%
ExodusPoint Capital Management, LP22,667$25.0K0.00%
Tower Research Capital LLC (TRC)7,568$8.00K0.00%

Sold out (2)

Institutions that held Lipocine Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of LPCN in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Pura Vida Investments, LLC54,738$77.0K
Charles Schwab Investment Management Inc36,595$52.0K